Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of IBI303 vs Adalimumab in Healthy Chinese Volunteers
NCT02912247Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of IBI303 in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriasis (2 arms), sponsored by Innovent Biologics. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable concentration at 71 days, Area under the concentration-time curve from time zero to infinity at 71 days and 1 more. Started Oct 2016; status: completed.
02
Drugs
IBI303
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriasis
Beyond the preview
Go deeper on NCT02912247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912247.